Analyst picks & changes

Amgen Inc.

(AMGN)

Merrill Lynch analyst Jeffrey Casdin raised his 1995 EPS estimate on the Thousand Oaks, Calif., company to $3.75 from $3.70. He noted that

Epogen

erythropoietin is continuing its growth spurt and that

Neupogen

Read the full 387 word article

How to gain access

Continue reading with a
two-week free trial.